ClinicalTrials.gg
CompletedNCT00754572Updated May 15, 2015Results posted

A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 70 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
18th of 113
418 · median 130
Started
2009
with 8 others
Phase 3
47 of 113
1 open now
Registered
32nd of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 18th largest by enrollment, is one of 9 that started in 2009, is one of 47 in phase 3, and was the 32nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm, open-label study will assess the safety and efficacy with regar d to reduction of signs and symptoms of treatment with tocilizumab in combinatio n with methotrexate, in patients with moderate to severe active rheumatoid arthr itis. Patients will receive tocilizumab 8mg/kg iv, every 4 weeks and methotrexat e 10-25mg weekly. The anticipated time on study treatment is 3-12 months, and th e target sample size is \<500 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients >=18 years with moderate to severe active RA for at least 6 months;
  • swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;
  • inadequate response to stable dose of MTX;
  • patients of must be using a reliable means of .

Exclusion criteria

Exclusion Criteria:

  • rheumatic disease other than RA;
  • patients with functional class IV RA;
  • diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;
  • prior treatment failure with anti-tumor necrosis factor agent;
  • pregnant or breastfeeding women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    1

    Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8mg/kg iv, every 4 weeks

  • 10-25mg oral or parenteral weekly.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24

    ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by Visual Analog Scale (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) 5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With ACR20 and ACR70 Response at Week 24

    ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)

    Time frame: Week 24

  2. Time to Onset of ACR20, ACR50, and ACR70

    ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)

    Time frame: Baseline and Week 24

  3. Change From Baseline in Hemoglobin at Week 24

    Time frame: Baseline and Week 24

  4. SJC and TJC at Baseline and Week 24

    The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

    Time frame: Baseline and Week 24

  5. Percent Change From Baseline in SJC and TJC at Week 24

    The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

    Time frame: Baseline and Week 24

  6. Pain as Assessed by the Participant at Baseline and Week 24

    The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

    Time frame: Baseline and Week 24

  7. Percent Change From Baseline in Pain as Assessed by the Participant at Week 24

    The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

    Time frame: Baseline and Week 24

  8. Participant's Global Assessment of Disease Activity at Baseline and Week 24

    The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

    Time frame: Baseline and Week 24

  9. Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24

    The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

    Time frame: Baseline and Week 24

  10. Physician's Global Assessment of Disease Activity at Baseline and Week 24

    The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

    Time frame: Baseline and Week 24

  11. Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24

    The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

    Time frame: Baseline and Week 24

  12. HAQ-DI at Baseline and Week 24

    HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

    Time frame: Baseline and Week 24

  13. Percent Change From Baseline in HAQ-DI at Week 24

    HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

    Time frame: Baseline and Week 24

  14. Area Under The Curve (AUC) of the ACR(n)

    ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent\*years.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  15. Percentage of Participants Achieving ACR20 Response

    ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the HAQ-DI 5. Acute phase reactant levels - ESR or CRP

    Time frame: Week 2

  16. Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models

    The probability of ACR positive response was determined using the GEE.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24

  17. Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24

    DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: Baseline and Week 24

  18. Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24

    DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \>1.2 with DAS28 \< 3.2; moderate response: change from baseline \>1.2 with DAS28 \>3.2 to \<5.1 or change from baseline \>0.6 to \<1.2 with DAS28 \<5.1; No response: change from baseline \< 0.6 or change from baseline \>0.6 and \<1.2 with DAS28 \>5.1.

    Time frame: Week 24

  19. AUC of DAS28

    The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.

    Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24

  20. Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.

    Time frame: Week 24

  21. Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24

    DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity and DAS28\<2.6 = remission

    Time frame: Week 24

  22. Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Time frame: Week 24

  23. Mean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF

    Time frame: Baseline and Week 24

07

Results

Posted May 15, 2015

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started418
Completed347
Not completed71
Withdrew: Adverse event19
Withdrew: Other39
Withdrew: Protocol violation3
Withdrew: Withdrawal by subject3
Withdrew: Lack of efficacy2
Withdrew: Death1
Withdrew: Administrative reason3
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24

ACR50 is defined as 50 percent (%) improvement in: a) Swollen Joints Count (SJC) and Tender Joints Count (TJC) and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by Visual Analog Scale (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) 5. Acute phase reactant levels - Erythrocyte Sedimentation Rate or C-Reactive Protein (ESR or CRP)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
percentage of participantsTocilizumab
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 2473.23 (68.78 to 77.67)
SecondaryPercentage of Participants With ACR20 and ACR70 Response at Week 24

ACR20 and ACR70 are defined as 20 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ACR20 and ACR70 Response at Week 24
percentage of participantsTocilizumab
ACR 2090.55 (87.61 to 93.49)
ACR 7050.39 (45.37 to 55.41)
SecondaryTime to Onset of ACR20, ACR50, and ACR70

ACR20, ACR50 and ACR70 are defined as 20, 50 and 70 percent improvement respectively in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain by VAS 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by HAQ-DI 5. Acute phase reactant (ESR or CRP)

Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemoglobin at Week 24
Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

SecondarySJC and TJC at Baseline and Week 24

The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

Time frame:
Baseline and Week 24
Reported as:
Mean · joints
SJC and TJC at Baseline and Week 24
jointsTocilizumab
TJC-Baseline25.06 ± 13.83
TJC-Week 244.57 ± 7.57
SJC-Baseline16.09 ± 8.69
SJC-Week 242.56 ± 4.26
SecondaryPercent Change From Baseline in SJC and TJC at Week 24

The number of swollen joints (66 joint count) were scored as swollen=1 and not swollen=0, and the number of tender joints (68 joint count ) were scored as tender=1 and not tender=0, and counted. Scores ranged from 0 to 66 for swollen joint counts and from 0 to 68 for tender joint counts. A positive change from baseline represents an improvement (a reduction in the number of swollen or tender joints).

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in SJC and TJC at Week 24
percent changeTocilizumab
TJC81.2 ± 28.1
SJC84.8 ± 22.5
SecondaryPain as Assessed by the Participant at Baseline and Week 24

The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · mm
Pain as Assessed by the Participant at Baseline and Week 24
mmTocilizumab
Baseline (n=384)68.01 ± 20.39
Week 24 (n=381)22.94 ± 22.53
SecondaryPercent Change From Baseline in Pain as Assessed by the Participant at Week 24

The participants assessed their pain using a 0 to 100 millimeter (mm) VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". The participants marked the line corresponding to the level of their pain and the distance from the left edge was measured. A positive change from baseline represents an improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Pain as Assessed by the Participant at Week 24
percent changeTocilizumab
Percent Change From Baseline in Pain as Assessed by the Participant at Week 2454.2 ± 177.0
SecondaryParticipant's Global Assessment of Disease Activity at Baseline and Week 24

The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

Time frame:
Baseline and Week 24
Reported as:
Mean · mm
Participant's Global Assessment of Disease Activity at Baseline and Week 24
mmTocilizumab
Baseline (n=384)69.46 ± 20.84
Week 24 (n=381)23.60 ± 22.68
SecondaryPercent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24

The participant's global assessment of disease activity is assessed on a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A positive change from baseline represents an improvement (reduced level of disease activity).

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 24
percent changeTocilizumab
Percent Change From Baseline in Participant's Global Assessment of Disease Activity at Week 2461.7 ± 43.1
SecondaryPhysician's Global Assessment of Disease Activity at Baseline and Week 24

The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

Time frame:
Baseline and Week 24
Reported as:
Mean · mm
Physician's Global Assessment of Disease Activity at Baseline and Week 24
mmTocilizumab
Baseline (n=384)67.32 ± 16.64
Week 24 (n=381)17.92 ± 18.16
SecondaryPercent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24

The physician's global assessment of disease activity is assessed on a 0 to 100 mm VAS by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity). The physicians marked the line corresponding to their assessment and the distance from the left edge was measured. A positive change from baseline represents an improvement (reduced level of disease activity).

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24
percent changeTocilizumab
Percent Change From Baseline in Physician's Global Assessment of Disease Activity at Week 2471.2 ± 38.7
SecondaryHAQ-DI at Baseline and Week 24

HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0 =without difficulties; 1= with some difficulties; 2=with great difficulties; and 3= unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
HAQ-DI at Baseline and Week 24
units on a scaleTocilizumab
Baseline (n=384)1.70 ± 0.63
Week 24 (n=376)0.79 ± 0.68
SecondaryPercent Change From Baseline in HAQ-DI at Week 24

HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. A positive change from baseline represents an improvement (reduced level of impairment).

Time frame:
Baseline and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in HAQ-DI at Week 24
percent changeTocilizumab
Percent Change From Baseline in HAQ-DI at Week 2452.0 ± 49.3
SecondaryArea Under The Curve (AUC) of the ACR(n)

ACR-n was defined as the lowest of 3 values (the percent change in the swollen joint count, the percent change in the tender joint count, and the median of the other 5 measures in the ACR core data set which included Participant's global assessment of pain (VAS), Participant's global assessment of disease activity (VAS), Investigator/Physician's global assessment of disease activity (VAS), Participant's assessment of disability measured by the HAQ-DI Acute phase reactant levels - ESR or CRP). Therefore, a percentage value was assigned to each participant at each timepoint. AUC was calculated for each participant from baseline to Week 112. Mean and standard deviation values are are provided in percent\*years.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Mean · percent*years
Area Under The Curve (AUC) of the ACR(n)
percent*yearsTocilizumab
Area Under The Curve (AUC) of the ACR(n)20.8 ± 9.4
SecondaryPercentage of Participants Achieving ACR20 Response

ACR20 is defined as 20% improvement in: a) SJC and TJC and b) Three of the following 5 assessments: 1. Participant's global assessment of pain (VAS) 2. Participant's global assessment of disease activity (VAS) 3. Investigator/Physician's global assessment of disease activity (VAS) 4. Participant's assessment of disability measured by the HAQ-DI 5. Acute phase reactant levels - ESR or CRP

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response
percentage of participantsTocilizumab
Percentage of Participants Achieving ACR20 Response40.10 (35.23 to 44.97)
SecondaryOdds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models

The probability of ACR positive response was determined using the GEE.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24
Reported as:
Number · odds
Odds Estimates for ACR Positive Response in Generalized Estimating Equation (GEE) Models
oddsTocilizumab
Week 2 Odds ACR500.10 (0.07 to 0.14)
Week 4 Odds ACR500.33 (0.27 to 0.42)
Week 8 Odds ACR500.87 (0.72 to 1.05)
Week 12 Odds ACR501.39 (1.14 to 1.69)
Week 16 Odds ACR501.55 (1.28 to 1.89)
Week 20 Odds ACR501.86 (1.52 to 2.27)
Week 24 Odds ACR502.39 (1.93 to 2.95)
Week 2 Odds ACR200.63 (0.51 to 0.76)
Week 4 Odds ACR201.50 (1.24 to 1.83)
Week 8 Odds ACR204.80 (3.73 to 6.19)
Week 12 Odds ACR204.80 (3.73 to 6.19)
Week 16 Odds ACR204.65 (3.61 to 5.97)
Week 20 Odds ACR206.46 (4.88 to 8.56)
Week 24 Odds ACR206.88 (5.16 to 9.18)
Week 4 Odds ACR700.08 (0.06 to 0.12)
Week 8 Odds ACR700.27 (0.21 to 0.34)
Week 12 Odds ACR700.41 (0.34 to 0.51)
Week 16 Odds ACR700.53 (0.44 to 0.65)
Week 20 Odds ACR700.75 (0.62 to 0.91)
Week 24 Odds ACR700.92 (0.76 to 1.12)
SecondaryChange From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24

DAS28 calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 24
score on a scaleTocilizumab
Change From Baseline in Disease Activity Score Based on 28 Joint Count (DAS28) at Week 244.4 ± 1.6
SecondaryPercentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24

DAS28- based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good response: change from baseline \>1.2 with DAS28 \< 3.2; moderate response: change from baseline \>1.2 with DAS28 \>3.2 to \<5.1 or change from baseline \>0.6 to \<1.2 with DAS28 \<5.1; No response: change from baseline \< 0.6 or change from baseline \>0.6 and \<1.2 with DAS28 \>5.1.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Response by Categorical DAS28 Responses According to The European League Against Rheumatism (EULAR Response) at Week 24
Percentage of ParticipantsTocilizumab
Good Response68.17 (63.60 to 72.74)
Moderate Response29.57 (25.10 to 34.05)
No Response2.26 (0.80 to 3.71)
SecondaryAUC of DAS28

The AUC was computed using the trapezoidal rule, considering baseline value as 0, through NCSS software. For each participant, AUC for DAS28 units was calculated. Each individual AUC DAS28 value was divided by 52 to have the conversion of AUC DAS28 in unit weeks to AUC DAS28 in unit years, as 1 week is approximately 1/52 years. The set of individual AUC DAS28 was computed as summary statistics.

Time frame:
Weeks 2, 4, 8, 12, 16, 20 and 24
Reported as:
Mean · scores on a scale * years
AUC of DAS28
scores on a scale * yearsTocilizumab
AUC of DAS2811.8 ± 4.2
SecondaryFatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.

Time frame:
Week 24
Reported as:
Mean · score on a scale
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 24
score on a scaleTocilizumab
Fatigue as Assessed Using the Functional Assessment of Chronic Illness Therapy (FACIT-Fatigue) Score at Week 2439.9 ± 9.4
SecondaryPercentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24

DAS28 calculated from the SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 (less than or equal to ) ≤3.2 = low disease activity, DAS28 (greater than) \>3.2 to 5.1 = moderate to high disease activity and DAS28\<2.6 = remission

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 24
percentage of participantsTocilizumab
Percentage of Participants Achieving Remission (DAS28 Less Than [<] 2.6) at Week 2448.41 (43.57 to 53.25)
SecondaryQuality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24

SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. Total of 3 variables were analyzed (2 composite subscales and vitality score). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

Time frame:
Week 24
Reported as:
Mean · score on a scale
Quality of Life (QoL) Assessed by Short-Form 36 (SF-36) at Week 24
score on a scaleTocilizumab
General Health42.5 ± 12.9
Physical functioning63.0 ± 24.2
Role limitations due to physical health64.0 ± 23.9
Role limitations due to emotional problems66.0 ± 24.1
Energy/fatigue48.9 ± 10.6
Emotional well-being54.5 ± 10.3
Social functioning38.2 ± 12.7
Pain63.6 ± 24.8
SecondaryMean Change in Rheumatoid Factor (RF) at Week 24 in Participants With Positive RF
Time frame:
Baseline and Week 24

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were recorded from the date of first dose of drug administration until the end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—30/418 (7.2%)324/418 (77.5%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventTocilizumab
PneumoniaInfections and infestations3/418
CellulitisInfections and infestations3/418
Leukopenia NOSBlood and lymphatic system disorders2/418
HypersensitivityImmune system disorders1/418
ConstipationGastrointestinal disorders1/418
AnaemiaBlood and lymphatic system disorders1/418
BradicardiaCardiac disorders1/418
BronchitisInfections and infestations1/418
Chronic gastrointestinal bleedingGastrointestinal disorders1/418
GastritisGastrointestinal disorders1/418
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTocilizumab
HypercholesterolemiaMetabolism and nutrition disorders71/418
Hepatic enzyme increasedInvestigations70/418
HeadacheNervous system disorders41/418
Urinary tract infectionInfections and infestations41/418
HypertriglyceridaemiaMetabolism and nutrition disorders39/418
HypertensionVascular disorders32/418
InfluenzaInfections and infestations32/418
PharyngitisInfections and infestations30/418
Leukopenia NOSBlood and lymphatic system disorders25/418
Back painMusculoskeletal and connective tissue disorders22/418

Baseline characteristics

Intention to treat (ITT) population: All participants who received at least one dose of study drug and who had at least one effectiveness measurement performed after baseline.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean48.69 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female371
Male47
08

Study locations

70 sites
  • Buenos Aires, C1280AEB, Argentina
  • Buenos Aires, C1425ASQ, Argentina
  • Buenos Aires, C1426AAL, Argentina
  • Córdoba, X5000FAL, Argentina
  • San Miguel De Tucuman, T4000IFP, Argentina
  • San Miguel, T4000AXL, Argentina
  • Salvador, BA 40050-410, Brazil
  • Fortaleza, CE 60170001, Brazil
  • Brasilia, DF 70840-901, Brazil
  • Vitoria, ES 29043-910, Brazil
  • Belo Horizonte, MG 30150-221, Brazil
  • Juiz de Fora, MG 36010-570, Brazil
  • Recife, PE 50000-000, Brazil
  • Curtiba, PR 80030-110, Brazil
  • Rio de Janeiro, RJ 20551-030, Brazil
  • Caxias do Sul, RS 95070-560, Brazil
  • Porto Alegre, RS 90035-003, Brazil
  • Porto Alegre, RS 90610-000, Brazil
  • Florianopolis, SC 88040-970, Brazil
  • Botucatu, SP 18600-400, Brazil
  • Campinas, SP 13059-900, Brazil
  • Campinas, SP 13083-888, Brazil
  • Ribeirao Preto, SP 14048-900, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Sao Paulo, SP 04027-000, Brazil
  • Sao Paulo, SP 04039-004, Brazil
  • Sao Paulo, SP 04266-010, Brazil
  • Concepcion, 1436, Chile
  • Santiago, 352, Chile
  • Santiago, 7500000, Chile
  • Santiago, 7550000, Chile
  • Santiago, 8320000, Chile
  • Santiago, 8380000, Chile
  • Santiago, 8860000, Chile
  • Temuco, 4780000, Chile
  • Barranquilla, Colombia
  • Bogota, 49 00, Colombia
  • Bogota, Colombia
  • Bogotá, Colombia
  • Bucaramanga, 0, Colombia
  • Cali, Colombia
  • Chia-Cundinamarca, Colombia
  • Medellin, Colombia
  • Medellín, 0, Colombia
  • Cartago, 0, Costa Rica
  • Heredia, 00, Costa Rica
  • San Jose, 10103, Costa Rica
  • San José, Costa Rica
  • Cuenca, Ecuador
  • Guayaquil, Ecuador
  • Quito, EC170517, Ecuador
  • Quito, Ecuador
  • Chihuahua, 31238, Mexico
  • Guadalajara, 44650, Mexico
  • Mexico City, 03900, Mexico
  • Mexico City, 11850, Mexico
  • Mexico City, 14140, Mexico
  • Miexico City, 06700, Mexico
  • Queretaro, 76000, Mexico
  • San Luis Potosi, 78240, Mexico
  • Arequipa, 04001, Peru
  • Jesus Maria, Peru
  • Lima, LIMA 14, Peru
  • San Isidro, Lima 27, Peru
  • Montevideo, 11000, Uruguay
  • Barquisimeto, 3005, Venezuela
  • Caracas, 1010, Venezuela
  • Caracas, 1040, Venezuela
  • Maracaibo, 4001, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 18, 2008
Start
Feb 2009
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
May 15, 2015
Last update
May 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00754572
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 18, 2008
Start date
Feb 2009
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
May 15, 2015
Last update
May 15, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion